Genomic Feature of a Rare Case of Mix Small-Cell and Large-Cell Neuroendocrine Lung Carcinoma: A Case Report

Youcai Zhu1,2, Feng Zhang3, Dong Yu3, Fang Wang3, Manxiang Yin1,2, Liangye Chen2, Chun Xiao2, Yueyan Huang4* and Feng Ding3,5*

1 The Center for Thoracic Diseases, Zhejiang Rongjun Hospital, Jiaxing, China, 2 Department of Pathology, The Hospital of Marine Police Corps of the Chinese People’s Armed Police Force, Jiaxing, China, 3 Precision Medicine Center, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, China, 4 Department of Pharmacy, Jiaxing University Medical College, Jiaxing, China, 5 Zhejiang Provincial Key Laboratory of Applied Enzymology, Yangtze Delta Region Institute of Tsinghua University, Jiaxing, China

Background: Cases of both small-cell (SCLC) and large-cell neuroendocrine lung carcinoma (LCNEC) were rarely reported. Although typical cases are morphologically distinct, the distinction between LCNEC and SCLC is still controversial, with some LCNECs showing close morphologies with SCLC. Here, we reported on a patient who had tumor with a mix of SCLC and LCNEC and uncovered these components’ histological and genomic features.

Case Presentation: A 59-year-old man was diagnosed with lung cancer and had resection surgery in our hospital. The H&E and immunohistochemistry staining revealed that the tumor had 30%–35% LCNEC and 65%–70% SCLC cells. The whole-exome sequencing (WES) identified no potentially actionable alteration in the tumor sample but found five alterations all with allele frequency over 90%, including TP53 p.R273H, MYH8 p.Q1814K, SLC17A6 p.W505L, PTPN5 p.M40I, and RB1 p.L267X. The genomic results supported that these two different components shared a similar dominant clonal origin. Furthermore, fluorescence in situ hybridization analysis revealed that the LCNECs have a higher copy number of MET than the SCLC component while without notable difference in the copy number of HER2 and TP53. Chemotherapy with pemetrexed and carboplatin was administrated for two cycles after the surgery. Although the chest CT showed remission in the lung, he was diagnosed with bone metastasis in 1 year later. Then, he received chemotherapy with etoposide and carboplatin but had severe side effect, leading to the discontinuation of the regime. Unfortunately, he returned to the local hospital with supportive care and died shortly after.

Conclusion: Based on these observations, we proposed that LCNEC and SCLC components in this patient may have a common clonal origin with dual mutations in TP53 and RB1, while the chromosome instability may cause multiple independent conversion that leads to LCNEC or SCLC morphologies.

Keywords: small cell lung cancer (SCLC), large-cell neuroendocrine lung carcinoma (LCNEC), genomic feature, FISH, case report, MET
INTRODUCTION

Although only approximately 13% of all lung cancer cases are small-cell lung cancer (SCLC), it remains the sixth most common cause of cancer-related death worldwide due to early metastasis and rapid progression (1). Meanwhile, large-cell neuroendocrine lung carcinoma (LCNEC) represents roughly 3% of all lung cancer cases. According to the fourth edition of the World Health Organization classification of lung tumors, it is categorized as a neuroendocrine tumor with SCLC (2). SCLC and LCNEC are mainly distinguished by morphological features; however, the definitive distinction is still controversial (3, 4). Although typical cases are morphologically distinct, some LCNECs showed close morphologies with SCLC (3, 4). Recent molecular characterization shed new light on the classification of SCLC and LCNEC tumors. Here, we reported on a 59-year-old male patient who had tumors with a mix of SCLC and LCNEC and analyzed their histological and genomic features.

CASE PRESENTATION

A 59-year-old man was transferred to our hospital in May 2015, with a 4.8 × 3.5 cm nodule with clear boundaries in the right lower field revealed by the chest computed tomography (Figure 1). Then, surgery was performed with video-assisted thoracoscopic resection of the right lower lobe and lymph nodes. The pathological evaluation showed a 6.0 × 4.0 × 3.3 cm tumor mass, and by hematoxylin–eosin (H&E) staining and immunohistochemistry (IHC) staining, it was demonstrated that 30%–35% of the tumor cells were LCNEC, and the rest 65%–70% were SCLC (Figure 2A). Both the small- and large-cell components were positive for NCAM (CD56), synaptophysin (Syn), and thyroid transcription factor-1 (TFF1) but negative for cytokeratin 19 (CK19), which were indicative of neuroendocrine tumor. The Ki67 staining was positive for both the small- and large-cell components, with the small cells having a high percentage of positive cells (67.5% versus 47.5%, Figure 2B).

In order to identify actionable genomic alterations to guide patient’s treatment, genetic testing of the whole tumor sample was performed. However, the whole-exome sequencing (WES) identified no actionable alteration in the tumor samples. WES data showed that, in addition to the high allele frequency (AF) of TP53 R273H (AF, 98.9%), which is a well-studied pathogenic mutation, alterations with high allele frequency were found in MYH8 (95.3%), SCL17A6 (93.1%), PTPN5 (92.1%), and RB1 (90.0%) (Table 1), indicating that both the SCLC and the LCNEC components were of the same mutant genotype. The RB1 c.799delC mutation was not reported in the ClinVar or COSMIC database, and as it resulted in a premature stop codon (p.L267X) that led to a non-functional protein, so it was classified as a novel pathogenic mutation. The SCL17A6 p.W505L was also not presented in ClinVar database but had been identified previously in lung cancer as documented in the COSMIC database with a highly pathogenic FATHMM score of 0.99. The MYH8 p.Q1814K and PTPN5 p.M40I had not been reported in the COSMIC database, indicating that they are likely to be novel mutations. Furthermore, fluorescence in situ hybridization test (Figure 3) showed that MET was amplified in the large-cell components with an average copy number of 5.51, whereas for the small-cell component, the MET
copy number was gained to 4.22 but did not reach the threshold of five copies per cell. To find out whether the cells were polyploid, HER2, CEP17, and TP53 were also tested, and three copies of HER2, CEP17, and TP53 (Figure 3) were detected in the large-cell component, but less than three copies of HER2, CEP17, and TP53 were detected in the small-cell component (Supplemental Figure S1). These results indicated that the large and small components of the tumor had different ploidy, which were also

TABLE 1 | High allele frequency mutations identified by WES in the tumor sample.

| Chr | Gene | Freq | Mut/Wt | Transcript | cDNA     | Protein | COSMIC | FATHMM | $\chi^2$ test |
|-----|------|------|--------|------------|----------|---------|--------|--------|---------------|
| 17  | TPS3 | 98.9%| 117/1  | NM_000546  | c.G818A  | p.R273H | 10660  | Pathogenic | 4.8E-12       |
| 17  | MYH8 | 95.3%| 212/13 | NM_002472  | c.C5440A | p.Q1814K| None   | Unknown | 2.2E-15       |
| 11  | SLC17A6 | 93.1%| 58/2  | NM_020346  | c.G1514T | p.W505L | 6132215 | Pathogenic | 6.6E-06       |
| 11  | PTPN5 | 92.1%| 76/3  | NM_006906  | c.G120T  | p.M40I  | None   | Unknown | 3.7E-07       |
| 13  | RB1  | 90.0%| 30/3  | NM_000321  | c.799delC| p.L267X | None   | Pathogenic | 8.8E-03       |

The $\chi^2$ test was done against an expected frequency of 70%.

FIGURE 2 | Immunohistochemistry staining of the SCLC and LCNEC regions. (A) H&E staining (400×); (B) immunohistochemistry staining of KI67, CK19, TFF1, CD56, and SYN (200×). The large-cell components were labeled within the red box.
validated by the evaluation of the single nucleotide polymorphism (SNP) frequency generated by WES of the tumor and non-tumoral lymph node samples. Additional whole chromosome trisomy was found on Chr3, 21, and 22; regional trisomy was found on Chr5, 9, and 11, and loss of heterozygosity (LOH) was found on Chr11 and 13 (Supplemental Figure S2).

Chemotherapy of 800 mg pemetrexed and 400 mg carboplatin was administrated for two cycles after the surgery. A year later, chest CT showed remission in the lung, but he was diagnosed with bone metastasis. Then, chemotherapy with 100 mg × 3 etoposide and 200 mg carboplatin was administrated. Unfortunately, the patient had severe side effect and did not continue with the regime; then, he returned to the local hospital with supportive care but died shortly after.

**MATERIAL AND METHODS**

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded (FFPE) tissue blocks were cut into 4-μm sections, deparaffinized in xylene, and rehydrated in a graded series of ethanol. Antigen retrieval was performed using citric (CK19, CD56, synaptophysin) or Tris–EDTA buffer (TTF-1 and Ki67). Immunohistochemistry was performed using primary antibodies and ultrasensitive second antibody kit (PV-9000, Zsbio Inc., Beijing). The following primary antibody working solutions were used: CK19 (ZM-0074), CD56 (ZM-0057), synaptophysin (Syn) (ZM-0246), TTF-1 (ZM-0250), and Ki67 (ZM-166).
DNA Extraction From FFPE Tissue
The FFPE sections were deparaffinized in dewaxing agent (Wuxi Jiangyuan Industrial and Trade Co., Jiangsu, China) at 60°C for 1 min, washed with 100% ethanol at room temperature, and air dried for 10 min. Genomic DNA was isolated from the tumor and lymph node FFPE samples by using the Biomark FFPE Genomic DNA Kit (Beijing ACCB Biotech, Beijing, China) in accordance with the manufacturer’s instructions.

Whole-Exome Sequencing and Data Analysis
DNA from FFPE sections of the tumor or lymph node were sequenced by Bionova (Beijing, China). Briefly, the DNA samples were fragmented and captured by IDT’s xGenExome Research Panel (Integrated DNA Technologies, San Diego, USA) and sequenced by using the Illumina HiSeq™ 4000 platform with 150 bp pair-end reads with a total coverage of 200x. The sequencing reads were aligned to the human reference genome hg19/GRCh37 using the Burrows–Wheeler Aligner tool, and the PCR duplicates were removed by using Picard v1.57 (http://picard.sourceforge.net/). GATK (https://software.broadinstitute.org/gatk/) were employed for variant calling. Variant annotation and interpretation were conducted through the use of ANNOVAR. Somatic mutations were defined as mutations found in the tumor tissue of the patient but not in the cancer-free lymph node.

FISH
FFPE sections of the tumor and lymph node were pretreated with Vysis Parafin Pretreatment IV (Abbott Molecular, IL) according to the manufacturer’s instruction. Probe mixture for HER2, MET, and TP53/CEP17 (Abbott Molecular, IL) was added onto the hybridization area, then coverslipped and sealed with rubber cement. Slides were incubated in Termobrite (Abbott) at 73°C for 5 min (HER2, TP53/CEP17) or 73°C for 3 min (MET) for denaturation, and hybridized at 37°C overnight. The sections were washed by using Post-Hybridization Wash Buffer Kit (Abbott). After gently removing the rubber cement and coverslip, the slides were washed in Washing Buffer II (HER2, TP53/CEP17) at 72°C for 2 min or Washing Buffer II (MET) at 74°C for 2 min. Then, the slides were washed briefly in 70% EtOH, air-dried in darkness, and stained with 4',6-diamidino-2-phenylindole (DAPI) counterstain and coverslipped. FISH results were examined with a BX43 fluorescence microscope (Olympus), and photographs were taken with a digital camera (CellSens) by using appropriate filters.

DISCUSSION
Although SCLC and LCNEC are distinguished by morphological features, the expression of the neuroendocrine markers such as CD56 and synaptophysin is indicative of a similar origin (3, 4). Recent molecular characterization showed that SCLC and LCNEC tumors had overlapping mutation profiles, which complicated their classification. In this study, the histological and genomic feature of a rare case of mix SCLC and LCNEC was analyzed. Although the tumor sample contained about a third of LCNEC cells, pathogenic alterations TP53 p.R273H and RB1 p.L267X were found at an AF of 98.9% and 90%, respectively, indicating that both the SCLC and LCNEC components harbored the pathogenic TP53 and RB1 alterations. The dual inactivation of TP53 and RB1 is a prominent feature for SCLC as reported by multiple independent studies (5–8). For LCNEC, genetic and gene expression analysis of 45 morphologically identified cases showed that 40% cases were SCLC-like as characterized by TP53 and RB1 co-mutation and gene expression profiles, and the rest 56% had the NSCLC-like profiles instead, lacking dual mutation in TP53 and RB1 (9). Since both LCNEC and SCLC are neuroendocrine tumors, in a study of 148 lung neuroendocrine tumors that included LCNEC, SCLC, and carcinoids, distinct mutational landscape was noticed for carcinoids and carcinomas, but LCNEC and SCLC showed similar mutational profiles except for the high prevalence of RB1 mutation in SCLC, and SMARCA2 mutation is found exclusively in LCNEC (10). A recent study on LCNEC, SCLC, and LC showed that RUNX1, ERBB4, BRCA1, and EPHA3 distinctly mutated in LCNEC, although the mutation frequency was moderate, and consistent with a previous study, 4/14 of LCNEC cases showed dual inactivation mutation in TP53 and RB1 (11). The result of the current study is in line with these reports, which highlighted the similarity of a subset of LCNEC to SCLC. Yet, due to that the SCLC and LCNEC cases were of independent patients, it is hard to conclude whether the SCLC and LCNEC subset had the same oncogenesis path. The current case study offered a unique opportunity to study the origin of SCLC and LCNEC. First, the SCLC and LCNEC components were derived from the same patient, rendering them identical in genetic background and environmental influences. Second, the SCLC and LCNEC components did not originate from separate locations but were present as multiple intermingled nests. Third, in addition to TP53 and RB1, high-frequency mutations in genes such as MYH8 (95.3%), SCL17A6 (93.1%), and PTPN5 (92.1%), which located on different chromosomes, were also identified. This indicated that the similarity of genetic mutation in SCLC and LCNEC components are unlikely to be originated independently; a more likely scenario is that the SCLC and LCNEC components had the same origin of early oncogenesis, and they were derived from the same mutant clone that harbors these mutations.

If the SCLC and the LCNEC components originated from the same clone, why were they of different morphologies? To answer this question, the best study would be to isolate the SCLC and LCNEC components and perform mutation and gene expression analysis on them. The intermingled growth of the SCLC and LCNEC components, however, made the dissection technically difficult. FISH study at the single cell level allowed a preliminary evaluation of the genetic differences of the two components. We found that the LCNEC portion had slightly higher copy numbers in MET, which indicated that after the initial clonal growth, subsets of cells diverged. Although MET copy number was above the threshold as a biomarker for TKI treatment, the SCLC had a higher Ki67 levels than the LCNEC component.

For patients with mix pathological tumor components, the prognosis was usually poor. The heterogeneity per se may indicate a high level of genomic instability, which renders the
tumor a higher chance to mutate and gain drug-resistant features. In addition, the subclones or the heterogeneous components may contain different signal transduction pathways, and the inhibition of one pathway may hinder the growth of a portion of cells but not the rest. The development of drugs that targets different subclones/components may be necessary for the effective control of tumor growth.

In summary, this study reports a rare case of mix SCLC and LCNEC. The molecular analysis indicated that the SCLC and LCNEC were derived from the same early clone that harbors TP53 and RB1 null mutations, and mutations in MYH8, SCL17A6, and PTPN5. We propose that LCNEC containing dual mutations in TP53 and RB1 can have a common clonal origin with SCLC, with the genomic instability that causes additional mutations for the diversion to LCNEC or SCLC.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

REFERENCES

1. Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota AK, Turrisi A, et al. The International Staging Project for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2016) 11(3):300–11. doi: 10.1016/j.jtho.2015.10.008

2. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol (2015) 10(9):1243–60. doi: 10.1097/JTO.0000000000000630

3. Ha SY, Han J, Kim WS, Suh BS, Roh MS. Interobserver Variability in Diagnosing High-Grade Neuroendocrine Carcinoma of the Lung and Comparing It With the Morphometric Analysis. Korean J Pathol (2012) 46(1):42–7. doi: 10.4132/KoreanPathol.2012.46.1.42

4. van Bakker MA, Willemsen S, Grunberg K, Noorduijn LA, van Oosterhout MF, van Suylen RJ, et al. Small Cell Carcinoma of the Lung and Large Cell Neuroendocrine Carcinoma: Interobserver Variability. HistoPathology (2010) 56(3):356–63. doi: 10.1111/j.1365-2559.2010.03486.x

5. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive Genomic Profiles of Small Cell Lung Cancer. Nature (2015) 524(7563):47–53. doi: 10.1038/nature14664

6. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative Genome Analyses Identify Key Somatic Driver Mutations of Small-Cell Lung Cancer. Nat Genet (2012) 44(10):1104–10. doi: 10.1038/ng.2396

7. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive Genomic Analysis Identifies SOX2 as a Frequently Amplified Gene in Small-Cell Lung Cancer. Nat Genet (2012) 44(10):1111–6. doi: 10.1038/ng.2405

8. Umemura S, Mimaki S, Makinoshima H, Tada S, Ishii G, Ohmatsu H, et al. Therapeutic Priority of the PI3K/AKT/mTOR Pathway in Small Cell Lung Cancers as Revealed by a Comprehensive Genomic Analysis. J Thorac Oncol (2014) 9(9):1324–31. doi: 10.1097/JTO.0000000000000250

9. Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, et al. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-Like and Non-Small Cell Carcinoma-Like Subsets. Clin Cancer Res (2016) 22(14):3618–29. doi: 10.1158/1078-0432.CCR-15-2946

10. Simbolo M, Maffiini A, Sikora KO, Fassan M, Barbi S, Corbo V, et al. Lung Neuroendocrine Tumours: Deep Sequencing of the Four World Health Organization Histotypes Reveals Chromatin-Remodelling Genes as Major Players and a Prognostic Role for TERT, RB1, MEN1 and KMT2D. J Pathol (2017) 241(4):488–500. doi: 10.1002/path.4853

11. Zhou Z, Zhu L, Niu X, Shen S, Zhao Y, Zhang J, et al. Comparison of Genomic Landscapes of Large Cell Neuroendocrine Carcinoma, Small Cell Lung Carcinoma, and Large Cell Carcinoma. Thorac Cancer (2019) 10:839–47. doi: 10.1111/1759-7714.13011

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee of Jiaxing University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YZ: manuscript writing. FZ: data collection and analysis. DY: project development. FD: project development and manuscript writing. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.794744/full#supplementary-material